Q5154 Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
Billable / valid for submission HCPCS Release 2026Q3
Short description: Inj, omlyclo, 5 mg
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg | yes |
Related codes in Q51
- Q5100 Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
- Q5112 Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
- Q5113 Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
- Q5114 Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
- Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
- Q5116 Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg
- Q5117 Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
- Q5118 Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
- Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
- Q5120 Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg
- Q5121 Injection, infliximab-axxq, biosimilar, (avsola), 10 mg